Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

UH conducts first ever pilot study to test heat therapy for treatment of PE

University Hospitals Case Medical Center is conducting the first ever pilot study to test a new procedure using "heat therapy" or local radiofrequency energy to treat premature ejaculation.

9 Mar 2011

5a-reductase inhibitors for male health problems can affect sexual health

A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.

7 Mar 2011

Biosante to purchase $25.1 million shares of common stock in registered direct offering

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from several institutional investors to purchase $25.1 million of securities in a registered direct offering.

5 Mar 2011

BioSante vaccine increases median survival of resected pancreatic cancer patients

BioSante Pharmaceuticals, Inc. today announced publication of results from a Phase II clinical study that show BioSante's Pancreas Cancer Vaccine increased the median survival of resected pancreatic cancer patients from 15 to 20 months, as reported in published data, to 24.8 months, an increase of more than 25 percent.

4 Mar 2011

EPO to grant patent for Apricus MycoVa product to treat nail fungus

Apricus Biosciences, Inc. announced today that the European Patent Office will grant a patent for the company's MycoVa product for treating onychomycosis.

2 Mar 2011

High blood pressure medications useful even in those without hypertension: Study

Researchers have studied existing evidence to suggest that people who have had a stroke or a heart attack might benefit from taking blood pressure medications, even if they do not have high blood. They noted that for every 1,000 people taking the drugs in clinical trials, on average 15 fewer died from heart disease than when the patients got dummy treatment. The study however could not explain the cause for this benefit. The study, which was funded by Tulane University and the National Institutes of Health, was published in the March 2 issue of the Journal of the American Medical Association.

1 Mar 2011

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.

28 Feb 2011

BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD

BioSante Pharmaceuticals, Inc. today announced that enrollment of subjects in the first of two pivotal Phase III LibiGel safety and efficacy trials has been completed.

24 Feb 2011

Study: Cannabis use may negatively impact male sexual performance

Rany Shamloul's recent review of the medical literature on cannabis use and sexual health has revealed that cannabis use may negatively impact male sexual performance.

23 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

Apricus Bio awards Neopharm exclusive rights to market and sell Vitaros in Israel and Palestinian Territories

Apricus Biosciences, Inc., announced today that it has entered into a licensing agreement granting Neopharm Group the exclusive rights to market and sell Vitaros®, Apricus Bio's treatment for erectile dysfunction ("ED") and, when and if available, its formulation for the treatment of premature ejaculation ("PE"), in Israel and the Palestinian Territories of the Gaza Strip and the West Bank.

15 Feb 2011

FDA waives NDA filing fee for Antares' Anturol NDA

Antares Pharma, Inc. today announced the receipt from the U.S. Food and Drug Administration (FDA) of a waiver, on February 8, 2011, for the $1,500,000 New Drug Application (NDA) filing fee for Anturol® Gel for overactive bladder (OAB).

14 Feb 2011

Positive safety data from BioSante's ongoing LibiGel Phase III study in women with HSDD

BioSante Pharmaceuticals, today announced positive safety data in its ongoing LibiGel Phase III clinical development program.

13 Feb 2011

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

Antares Pharma, Inc. today announced that the first patient has been dosed in a clinical study evaluating the VIBEX™ MTX product which is being developed for the treatment of rheumatoid arthritis. The clinical study will evaluate several dose strengths of VIBEX MTX delivered with a proprietary autoinjector versus conventional needle and syringe administration by a healthcare professional.

2 Feb 2011

NexMed presents data on NexACT technology use to improve less permeable, soluable oral drugs

Apricus Biosciences, today announced that its research and development team at its NexMed, USA, Inc. subsidiary is presenting data demonstrating the use of the Company's proprietary NexACT technology to improve less permeable or less soluable drugs, at the Controlled Release Society Product Development Forum for Poorly Soluble Drugs, being held January 27 to 29, 2011, in Miami, Florida.

29 Jan 2011

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for its Melanoma Cancer Vaccine in the treatment of stage IIb to IV melanoma, from the FDA's Office of Orphan Products Development. Melanoma is the most deadly form of skin cancer.

25 Jan 2011

Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, announced that Teva Pharmaceutical Industries Limited (Teva) purchased 2,334,515 shares of Rexahn's common stock in a private offering for $3.95 million, or $1.692 per share.

21 Jan 2011

Health Canada approves Labopharm's OLEPTRO for treatment of Major Depressive Disorder

Labopharm Inc. today announced that Health Canada's Therapeutic Products Directorate (TPD) has approved OLEPTRO, a novel once-daily formulation of the antidepressant trazodone, for the symptomatic relief of Major Depressive Disorder in adults.

21 Jan 2011

Apricus Bio's MycoVa demonstrates 'non-inferiority' for treatment of onychomycosis compared to Loceryl

Apricus Biosciences, Inc. today announced that an additional analysis conducted on behalf of the Company has shown that MycoVa™ has successfully demonstrated 'non-inferiority' for the treatment of onychomycosis (commonly referred to as nail fungus), compared to the current standard of care in Europe for topical therapy, Loceryl®.

20 Jan 2011

LibiGel may be the first FDA approved product to treat HSDD in menopausal women

BioSante Pharmaceuticals, Inc., a pharmaceutical company developing products for the treatment of female sexual health, today announced results of a survey of over 100 Obstetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD).

11 Jan 2011

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

UH conducts first ever pilot study to test heat therapy for treatment of PE

5a-reductase inhibitors for male health problems can affect sexual health

Biosante to purchase $25.1 million shares of common stock in registered direct offering

BioSante vaccine increases median survival of resected pancreatic cancer patients

EPO to grant patent for Apricus MycoVa product to treat nail fungus

High blood pressure medications useful even in those without hypertension: Study

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD

Study: Cannabis use may negatively impact male sexual performance

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Bio awards Neopharm exclusive rights to market and sell Vitaros in Israel and Palestinian Territories

FDA waives NDA filing fee for Antares' Anturol NDA

Positive safety data from BioSante's ongoing LibiGel Phase III study in women with HSDD

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

NexMed presents data on NexACT technology use to improve less permeable, soluable oral drugs

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117

Health Canada approves Labopharm's OLEPTRO for treatment of Major Depressive Disorder

Apricus Bio's MycoVa demonstrates 'non-inferiority' for treatment of onychomycosis compared to Loceryl

LibiGel may be the first FDA approved product to treat HSDD in menopausal women

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in